Drug
Obeticholic Acid 5 MG
Obeticholic Acid 5 MG is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
33%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Not yet recruiting1
Withdrawn1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (50.0%)
Phase 31 (50.0%)
Trials by Status
not_yet_recruiting133%
withdrawn133%
completed133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
NCT05239468
not_yet_recruitingphase_3
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes
NCT06691412
withdrawn
A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients
NCT05293938
Clinical Trials (3)
Showing 3 of 3 trials
NCT05239468Phase 2
Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
NCT06691412Phase 3
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes
NCT05293938
A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3